Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Inspections To Target 55% Of “High-Risk” Manufacturers In FY 2004

Executive Summary

FDA inspections will target 55% of "high-risk" drug manufacturers during fiscal year 2004

You may also be interested in...

FDA Plays Up Police Role; “White Paper” Recaps Recent Enforcement Steps

An FDA "White Paper" highlighting the agency's recent enforcement actions is part of a concerted effort to draw consumer, industry and media attention to the agency's role in policing industry

FDA Inspections To Focus On Sterile Rx, New Facilities In FY 2003

FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts